TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from SynAct Pharma AB ( (SE:SYNACT) ) is now available.
SynAct Pharma AB announced that Hunter Capital AB has acquired 1,375,000 warrants and 500,000 shares from Heights Capital Management. This transaction is seen as a strategic move to enhance stability and predictability in SynAct’s shareholder base, as Hunter Capital has agreed not to convert the warrants into shares, allowing SynAct to focus on its strategic and developmental goals.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm, focusing on the resolution of inflammation through the selective activation of the melanocortin system. The company offers a broad portfolio of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activity, helping patients achieve immune balance.
YTD Price Performance: 112.16%
Average Trading Volume: 155,880
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.01B
Learn more about SYNACT stock on TipRanks’ Stock Analysis page.